May 2020, Drugs Monitor

(28 May 2020) Chloroquine & Hydroxychloroquine- S-HCQ found to be 60% more active against SARS-CoV-2 than R-HCQ, in-vitro

May 28, 2020

Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19 https://doi.org/10.1101/2020.05.26.114033 In all of the clinical trials for COVID-19 conducted thus far and among those ongoing involving chloroquine or… Continue reading "(28 May 2020) Chloroquine & Hydroxychloroquine- S-HCQ found to be 60% more active against SARS-CoV-2 than R-HCQ, in-vitro"

(27 May 2020) Remdesivir- no significant difference between a 5-day and a 10-day course

May 28, 2020

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2015301?query=featured_home In a randomized, open-label, phase 3 trial (NCT04292899)involving hospitalized patients with confirmed SARS-CoV-2 infection. In total, 397 patients underwent randomization and began treatment (200 patients for 5 days… Continue reading "(27 May 2020) Remdesivir- no significant difference between a 5-day and a 10-day course"

(26 May 2020) Tocilizumab- rapid beneficial effect on fever and inflammatory markers

May 27, 2020

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy https://doi.org/10.1016/j.ejim.2020.05.011 In this open-label prospective study clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab are described. Forty-five patients… Continue reading "(26 May 2020) Tocilizumab- rapid beneficial effect on fever and inflammatory markers"

(25 May 2020) Hydroxychloroquine & Tocilizumab- HCQ no survival benefit, TCZ improved survival

May 25, 2020

Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational Study https://doi.org/10.1101/2020.05.21.20109207 Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of… Continue reading "(25 May 2020) Hydroxychloroquine & Tocilizumab- HCQ no survival benefit, TCZ improved survival"

(24 May 2020) Arbidol- Arbidol/IFN-α2b combination did not accelerate virus clearance

May 25, 2020

Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study https://doi.org/10.1016/j.micinf.2020.05.012 This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged… Continue reading "(24 May 2020) Arbidol- Arbidol/IFN-α2b combination did not accelerate virus clearance"

(23 May 2020) Heparin- evidence of heparin resistance in critically unwell COVID-19 patients

May 24, 2020

Heparin resistance in COVID-19 patients in the intensive care unit https://link.springer.com/article/10.1007/s11239-020-02145-0 In a cohort of 69 intensive care unit (ICU) patients authors investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation. 15 of the patients have… Continue reading "(23 May 2020) Heparin- evidence of heparin resistance in critically unwell COVID-19 patients"

(22 May 2020) Remdesivir- shortened time to recovery

May 23, 2020

Remdesivir for the Treatment of Covid-19 — Preliminary Report https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time… Continue reading "(22 May 2020) Remdesivir- shortened time to recovery"

(21 May 2020) Lopinavir/Ritonavir- Earlier administration of LPV/r treatment could shorten viral shedding duration

May 22, 2020

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection https://erj.ersjournals.com/content/early/2020/05/13/13993003.00799-2020 In a retrospective study of the 120 patients, 78 patients (65%) were administered with LPV/r treatment. The median duration of… Continue reading "(21 May 2020) Lopinavir/Ritonavir- Earlier administration of LPV/r treatment could shorten viral shedding duration"

(19 May 2020) Lopinavir/Ritonavir- higher concentrations are required to reach the assumed EC50

May 20, 2020

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) https://www.acpjournals.org/doi/10.7326/M20-1550 This reports the first pharmacokinetic data of lopinavir and ritonavir in patients hospitalized with COVID-19. Lopinavir trough levels were approximately 2-fold higher in COVID population than… Continue reading "(19 May 2020) Lopinavir/Ritonavir- higher concentrations are required to reach the assumed EC50"

(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients

May 20, 2020

Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study https://doi.org/10.1101/2020.05.14.20099234 In an observational study, among 86 patients, 21 received Tocilizumab during the hospital stay. Both the Cox model… Continue reading "(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients"

Month: May 2020